Pharmacokinetics and Safety of the Novel Sulfactam Antibiotic BAL30072 after Single Ascending Dose Infusions in Healthy Volunteers.

Trial Profile

Pharmacokinetics and Safety of the Novel Sulfactam Antibiotic BAL30072 after Single Ascending Dose Infusions in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2011

At a glance

  • Drugs BAL 30072 (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 17 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 25 May 2011 Positive tolerability and pharmacokinetic results reported in a Basilea Pharmaceuticals media release.
    • 25 May 2011 Status changed from recruiting to completed, according to information in a Basilea Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top